Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140


FANCM, RAD1, CHEK1 and TP53I3 act as BRCA-like tumor suppressors and are mutated in hereditary ovarian cancer.

Lopes JL, Chaudhry S, Lopes GS, Levin NK, Tainsky MA.

Cancer Genet. 2019 Jun;235-236:57-64. doi: 10.1016/j.cancergen.2019.04.061. Epub 2019 May 9.


Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance.

Farran B, Albayrak S, Abrams J, Tainsky MA, Levin NK, Morris R, Matherly LH, Ratnam M, Winer I.

Cancer Med. 2019 Mar;8(3):920-927. doi: 10.1002/cam4.1944. Epub 2019 Feb 13.


Utilizing iVariantGuide for Variant Assessment of Next-Generation Sequencing.

Chaudhry SR, Tainsky MA.

Curr Protoc Bioinformatics. 2019 Mar;65(1):e73. doi: 10.1002/cpbi.73. Epub 2019 Feb 12.


Germline and Somatic NF1 Alterations Are Linked to Increased HER2 Expression in Breast Cancer.

Wang X, Kallionpää RA, Gonzales PR, Chitale DA, Tousignant RN, Crowley JP, Chen Z, Yoder SJ, Blakeley JO, Acosta MT, Korf BR, Messiaen LM, Tainsky MA.

Cancer Prev Res (Phila). 2018 Oct;11(10):655-664. doi: 10.1158/1940-6207.CAPR-18-0072. Epub 2018 Aug 13.


Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer.

Chatterjee M, Hurley LC, Levin NK, Stack M, Tainsky MA.

Cancer Biomark. 2017 Dec 6;20(4):369-387. doi: 10.3233/CBM-170652.


Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer.

Wang X, Teer JK, Tousignant RN, Levin AM, Boulware D, Chitale DA, Shaw BM, Chen Z, Zhang Y, Blakeley JO, Acosta MT, Messiaen LM, Korf BR, Tainsky MA.

Genes Chromosomes Cancer. 2018 Jan;57(1):19-27. doi: 10.1002/gcc.22503. Epub 2017 Sep 30.


Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer.

Chatterjee M, Hurley LC, Tainsky MA.

Gynecol Oncol Rep. 2017 Jun 15;21:37-44. doi: 10.1016/j.gore.2017.06.006. eCollection 2017 Aug. Review.


Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.

Stafford JL, Dyson G, Levin NK, Chaudhry S, Rosati R, Kalpage H, Wernette C, Petrucelli N, Simon MS, Tainsky MA.

PLoS One. 2017 Jun 7;12(6):e0178450. doi: 10.1371/journal.pone.0178450. eCollection 2017.


Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.

Ahsan S, Ge Y, Tainsky MA.

Oncotarget. 2016 Aug 30;7(35):57171-57185. doi: 10.18632/oncotarget.11036.


Telomere dysfunction and chromothripsis.

Ernst A, Jones DT, Maass KK, Rode A, Deeg KI, Jebaraj BM, Korshunov A, Hovestadt V, Tainsky MA, Pajtler KW, Bender S, Brabetz S, Gröbner S, Kool M, Devens F, Edelmann J, Zhang C, Castelo-Branco P, Tabori U, Malkin D, Rippe K, Stilgenbauer S, Pfister SM, Zapatka M, Lichter P.

Int J Cancer. 2016 Jun 15;138(12):2905-14. doi: 10.1002/ijc.30033. Epub 2016 Feb 29.



Tainsky MA, Morris RT.

Cancer Metastasis Rev. 2015 Mar;34(1):3. doi: 10.1007/s10555-014-9548-7. No abstract available.


Gene expression profiling of replicative and induced senescence.

Purcell M, Kruger A, Tainsky MA.

Cell Cycle. 2014;13(24):3927-37. doi: 10.4161/15384101.2014.973327.


Serum prognostic biomarkers in head and neck cancer patients.

Lin HS, Siddiq F, Talwar HS, Chen W, Voichita C, Draghici S, Jeyapalan G, Chatterjee M, Fribley A, Yoo GH, Sethi S, Kim H, Sukari A, Folbe AJ, Tainsky MA.

Laryngoscope. 2014 Aug;124(8):1819-26. doi: 10.1002/lary.24567. Epub 2014 Jan 29.


RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.

Sun D, Haddad R, Kraniak JM, Horne SD, Tainsky MA.

Mol Cancer Res. 2013 Jun;11(6):616-27. doi: 10.1158/1541-7786.MCR-12-0593. Epub 2013 Feb 19.


Variants in the Signaling Protein TSAd are Associated with Susceptibility to Ovarian Cancer in BRCA1/2 Negative High Risk Families.

Kaplun L, Fridman AL, Chen W, Levin NK, Ahsan S, Petrucelli N, Barrick JL, Gold R, Land S, Simon MS, Morris RT, Munkarah AR, Tainsky MA.

Biomark Insights. 2012;7:151-7. doi: 10.4137/BMI.S10815. Epub 2012 Dec 12.


Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area.

Wang X, Levin AM, Smolinski SE, Vigneau FD, Levin NK, Tainsky MA.

Am J Med Genet A. 2012 Dec;158A(12):3061-4. doi: 10.1002/ajmg.a.35560. Epub 2012 Sep 10.


Oncogene Mutation Survey in MPNST Cell Lines Enhances the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and Malignancy.

Sun D, Tainsky MA, Haddad R.

Transl Oncogenomics. 2012;5:1-7. doi: 10.4137/TOG.S8830. Epub 2012 Jan 18.


Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses.

Li Q, Tainsky MA.

PLoS One. 2011;6(12):e28683. doi: 10.1371/journal.pone.0028683. Epub 2011 Dec 14.


Diverse system stresses: common mechanisms of chromosome fragmentation.

Stevens JB, Abdallah BY, Liu G, Ye CJ, Horne SD, Wang G, Savasan S, Shekhar M, Krawetz SA, Hüttemann M, Tainsky MA, Wu GS, Xie Y, Zhang K, Heng HH.

Cell Death Dis. 2011 Jun 30;2:e178. doi: 10.1038/cddis.2011.60.


CREG1 enhances p16(INK4a) -induced cellular senescence.

Moolmuang B, Tainsky MA.

Cell Cycle. 2011 Feb 1;10(3):518-30. Epub 2011 Feb 1.


Higher miRNA tolerance in immortal Li-Fraumeni fibroblasts with abrogated interferon signaling pathway.

Li Q, Tainsky MA.

Cancer Res. 2011 Jan 1;71(1):255-65. doi: 10.1158/0008-5472.CAN-10-1452.


Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence.

Chatterjee M, Dyson G, Levin NK, Shah JP, Morris R, Munkarah A, Tainsky MA.

Cancer Biomark. 2012;11(2-3):59-73.


Myeloperoxidase and free iron levels: potential biomarkers for early detection and prognosis of ovarian cancer.

Fletcher NM, Jiang Z, Ali-Fehmi R, Levin NK, Belotte J, Tainsky MA, Diamond MP, Abu-Soud HM, Saed GM.

Cancer Biomark. 2011-2012;10(6):267-75. doi: 10.3233/CBM-2012-0255.


The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors.

Kraniak JM, Sun D, Mattingly RR, Reiners JJ Jr, Tainsky MA.

Mol Cell Biochem. 2010 Nov;344(1-2):267-76. doi: 10.1007/s11010-010-0551-1. Epub 2010 Aug 1.


Analysis of the expression of human tumor antigens in ovarian cancer tissues.

Ali-Fehmi R, Chatterjee M, Ionan A, Levin NK, Arabi H, Bandyopadhyay S, Shah JP, Bryant CS, Hewitt SM, O'Rand MG, Alekseev OM, Morris R, Munkarah A, Abrams J, Tainsky MA.

Cancer Biomark. 2010;6(1):33-48. doi: 10.3233/CBM-2009-0117.


Autoantibodies as biomarkers for ovarian cancer.

Chatterjee M, Tainsky MA.

Cancer Biomark. 2010-2011;8(4-5):187-201. doi: 10.3233/CBM-2011-0213. Review.


Genomic and proteomic biomarkers for cancer: a multitude of opportunities.

Tainsky MA.

Biochim Biophys Acta. 2009 Dec;1796(2):176-93. doi: 10.1016/j.bbcan.2009.04.004. Epub 2009 May 4. Review.


Detecting tumor-specific autoantibodies for cancer diagnosis: a technology overview.

Dudas SP, Tainsky MA.

Expert Opin Med Diagn. 2009 May;3(3):251-61. doi: 10.1517/17530050902832848. Epub 2009 Apr 8.


Discovery of antibody biomarkers using protein microarrays of tumor antigens cloned in high throughput.

Chatterjee M, Wojciechowski J, Tainsky MA.

Methods Mol Biol. 2009;520:21-38. doi: 10.1007/978-1-60327-811-9_3.


Predictors of decision making in families at risk for inherited breast/ovarian cancer.

Mellon S, Janisse J, Gold R, Cichon M, Berry-Bobovski L, Tainsky MA, Simon MS.

Health Psychol. 2009 Jan;28(1):38-47. doi: 10.1037/a0012714.


Usage of cancer associated autoantibodies in the detection of disease.

Dudas SP, Chatterjee M, Tainsky MA.

Cancer Biomark. 2010;6(5-6):257-70. doi: 10.3233/CBM-2009-0138. Review.


Cancer biomarker discovery: speed-bumps and tire shredders.

Tainsky MA.

Cancer Biomark. 2010;6(5-6):225-7. doi: 10.3233/CBM-2009-0147. No abstract available.


Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.

Balan V, Nangia-Makker P, Schwartz AG, Jung YS, Tait L, Hogan V, Raz T, Wang Y, Yang ZQ, Wu GS, Guo Y, Li H, Abrams J, Couch FJ, Lingle WL, Lloyd RV, Ethier SP, Tainsky MA, Raz A.

Cancer Res. 2008 Dec 15;68(24):10045-50. doi: 10.1158/0008-5472.CAN-08-3224.


Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Dilworth JT, Wojtkowiak JW, Mathieu P, Tainsky MA, Reiners JJ Jr, Mattingly RR, Hancock CN.

Cancer Biol Ther. 2008 Dec;7(12):1938-46. Epub 2008 Dec 7.


Critical pathways in cellular senescence and immortalization revealed by gene expression profiling.

Fridman AL, Tainsky MA.

Oncogene. 2008 Oct 9;27(46):5975-87. doi: 10.1038/onc.2008.213. Epub 2008 Aug 18. Review.


Risk perception and cancer worries in families at increased risk of familial breast/ovarian cancer.

Mellon S, Gold R, Janisse J, Cichon M, Tainsky MA, Simon MS, Korczak J.

Psychooncology. 2008 Aug;17(8):756-66. doi: 10.1002/pon.1370.


Interferon regulatory factors IRF5 and IRF7 inhibit growth and induce senescence in immortal Li-Fraumeni fibroblasts.

Li Q, Tang L, Roberts PC, Kraniak JM, Fridman AL, Kulaeva OI, Tehrani OS, Tainsky MA.

Mol Cancer Res. 2008 May;6(5):770-84. doi: 10.1158/1541-7786.MCR-07-0114.


Non-traditional immunogens and their application to immunotherapy.

Chatterjee M, Tainsky MA.

Curr Opin Mol Ther. 2008 Feb;10(1):62-7. Review.


Autoantibody approach for serum-based detection of head and neck cancer.

Lin HS, Talwar HS, Tarca AL, Ionan A, Chatterjee M, Ye B, Wojciechowski J, Mohapatra S, Basson MD, Yoo GH, Peshek B, Lonardo F, Pan CJ, Folbe AJ, Draghici S, Abrams J, Tainsky MA.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2396-405.


Concerns and recommendations regarding inherited cancer risk: the perspectives of survivors and female relatives.

Mellon S, Berry-Bobovski L, Gold R, Levin N, Tainsky MA.

J Cancer Educ. 2007 Fall;22(3):168-73.


Pathways to implementation of serum proteomics for cancer.

Chatterjee M, Levin NK, Shah JP, Ionan A, Grates HE, Tainsky MA.

Expert Opin Med Diagn. 2007 Sep;1(1):3-15. doi: 10.1517/17530059.1.1.3.


Mutations in SIRT2 deacetylase which regulate enzymatic activity but not its interaction with HDAC6 and tubulin.

Nahhas F, Dryden SC, Abrams J, Tainsky MA.

Mol Cell Biochem. 2007 Sep;303(1-2):221-30. Epub 2007 May 22.


Sphingomyelin synthase 1 suppresses ceramide production and apoptosis post-photodamage.

Separovic D, Hanada K, Maitah MY, Nagy B, Hang I, Tainsky MA, Kraniak JM, Bielawski J.

Biochem Biophys Res Commun. 2007 Jun 22;358(1):196-202. Epub 2007 Apr 23.


Epigenetic and functional analysis of IGFBP3 and IGFBPrP1 in cellular immortalization.

Fridman AL, Rosati R, Li Q, Tainsky MA.

Biochem Biophys Res Commun. 2007 Jun 8;357(3):785-91. Epub 2007 Apr 12.


Epitomics: global profiling of immune response to disease using protein microarrays.

Chatterjee M, Ionan A, Draghici S, Tainsky MA.

OMICS. 2006 Winter;10(4):499-506. Review.


Update on ovarian cancer screening.

Munkarah A, Chatterjee M, Tainsky MA.

Curr Opin Obstet Gynecol. 2007 Feb;19(1):22-6. Review.


Multianalyte tests for the early detection of cancer: speedbumps and barriers.

Tainsky MA, Chatterjee M, Levin NK, Draghici S, Abrams J.

Biomark Insights. 2007 Jul 10;2:261-7.


Expression profiling identifies three pathways altered in cellular immortalization: interferon, cell cycle, and cytoskeleton.

Fridman AL, Tang L, Kulaeva OI, Ye B, Li Q, Nahhas F, Roberts PC, Land SJ, Abrams J, Tainsky MA.

J Gerontol A Biol Sci Med Sci. 2006 Sep;61(9):879-89.


Microtubule deacetylases, SirT2 and HDAC6, in the nervous system.

Southwood CM, Peppi M, Dryden S, Tainsky MA, Gow A.

Neurochem Res. 2007 Feb;32(2):187-95. Epub 2006 Aug 25.


Supplemental Content

Loading ...
Support Center